Ciprandi Giorgio, Natoli Valentina, Puccinelli Paola, Incorvaia Cristoforo
Department of Internal Medicine, Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.), Azienda Ospedaliera Universitaria San Martino-IST, Largo R. Benzi 10, 16132 Genoa, Italy.
Scientific, Pharmacovigilance and Regulatory Department Stallergenes, Milan, Italy.
Allergy Asthma Clin Immunol. 2017 Feb 21;13:11. doi: 10.1186/s13223-017-0185-x. eCollection 2017.
As standard drug treatment of allergic rhinitis (AR) is not completely satisfactory, allergen immunotherapy (AIT) represents the only current treatment with the potential to modify the natural history. House dust mite (HDM) allergy is very common. The aim of the current experience was to describe the clinical profile of HDM-allergic patients with AR who received AIT in a real world model, such as allergy clinics. Globally, 239 patients (126 adults and 113 children; 107 females and 132 males; mean age 21 years, age range 6-56 years) were evaluated. AIT was prescribed in 59 patients (24.7%), 44 adults (35%) and 15 children (13.3%). The current findings deriving from this real world multicentre study are consistent with previous investigations on HDM-AIT and define some clinical characteristics of the eligible candidate to this treatment. In fact, severity of ocular-nasal symptoms and over-use of symptomatic medications may typify the ideal candidate to HDM-AIT and SLIT was the preferred choice.
由于变应性鼻炎（AR）的标准药物治疗并不完全令人满意，变应原免疫疗法（AIT）是目前唯一有可能改变自然病程的治疗方法。屋尘螨（HDM）过敏非常常见。本研究的目的是描述在过敏诊所等真实世界模型中接受AIT的HDM过敏AR患者的临床特征。全球共评估了239例患者（126例成人和113例儿童；107例女性和132例男性；平均年龄21岁，年龄范围6 - 56岁）。59例患者（24.7%）接受了AIT，其中44例成人（35%）和15例儿童（13.3%）。这项真实世界多中心研究的当前发现与先前关于HDM - AIT的研究一致，并确定了该治疗方法合适候选者的一些临床特征。事实上，眼鼻症状的严重程度和对症药物过度使用可能是HDM - AIT理想候选者的典型特征，而舌下免疫治疗（SLIT）是首选。
